Clinical Trials Browser

Phase 2/3 × Bevacizumab × Gastrointestinal × Clear all

NCT07490262 2026-04-16

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

Phase 2/3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07293468 2026-04-09

BIIRTH

Phase 2/3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07221357 2026-03-31

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Phase 2/3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05665348 2026-03-09

TRIPLET

Phase 2/3 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT07392866 2026-02-09

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

Phase 2/3 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05945901 2025-11-18

A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06109272 2025-08-15

LIVIGNO-2

Phase 2/3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06280495 2025-05-30

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Phase 2/3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05141721 2025-05-16

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05462613 2024-12-20

REPROGRAM-02

Phase 2/3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04547166 2024-10-17

A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)

Phase 2/3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03414983 2023-11-18

CheckMate 9X8

Phase 2/3 Completed

196 enrolled 26 charts

Gastrointestinal

Colorectal Neoplasms

NCT05976568 2023-08-04

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Phase 2/3 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT00952029 2020-03-30

Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer

Phase 2/3 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03686254 2018-09-26

The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM

Phase 2/3 Unknown

Gastrointestinal

Colonic Neoplasms

NCT00384176 2017-04-14

HORIZON III

Phase 2/3 Completed

1,814 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT00450203 2016-12-01

ST03

Phase 2/3 Unknown

Gastrointestinal

Oesophagogastric Cancer

NCT00735241 2015-05-22

FAST

Phase 2/3 Withdrawn

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT00975897 2013-12-19

Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer

Phase 2/3 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00294359 2007-08-22

The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer

Phase 2/3 Completed

Gastrointestinal

Colorectal Neoplasms